<DOC>
	<DOCNO>NCT02727907</DOCNO>
	<brief_summary>Study design double-blind , randomize , placebo-controlled study 3 parallel group use active comparator placebo . Total duration therapy 2 year . Study hypothesis equivalence efficacy safety investigational drug BCD-033 original drug RebifÂ® .</brief_summary>
	<brief_title>Study Efficacy Safety Drugs BCD-033 Rebif Treatment Patients With Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>1 . Age 1855 2 . Patients gender Multiple Sclerosis ( McDonald criterion 2010 ) 3 . No relapse 28 day randomisation 4 . Expanded Disability Status Scale score 05,5 Exclusion Criteria 1 . Primary secondary progression Multiple Sclerosis 2 . Expanded Disability Status Scale score 5,5 3 . Severe depression , suicide idea and/or attempt 4 . Systemic corticosteroid application 30 day randomisation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>